Adverum Biotechnologies/ADVM

$11.73

-2%
-
1D1W1MYTD1YMAX

About Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Ticker

ADVM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Laurent Fischer

Employees

121

Headquarters

Redwood city, United States

ADVM Metrics

BasicAdvanced
$248.64M
Market cap
-
P/E ratio
-$11.62
EPS
0.82
Beta
-
Dividend rate
$248.64M
0.81732
$29.70
$7.10
269.59K
4.125
-48.68%
-88.43%
-55.24%
69.068
1.456
2.979
25.38%

What the Analysts think about ADVM

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
241.01% upside
High $60.00
Low $20.00
$11.73
Current price
$40.00
Average price target

ADVM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-23.7M
-27.74%
Profit margin
0%
-

ADVM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 31.68%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$2.90
-$3.10
-$3.30
-$2.30
-
Expected
-$3.20
-$3.29
-$3.15
-$3.37
-$1.41
Surprise
-9.49%
-5.72%
4.71%
-31.68%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Adverum Biotechnologies stock?

Adverum Biotechnologies (ADVM) has a market cap of $248.64M as of April 13, 2024.

What is the P/E ratio for Adverum Biotechnologies stock?

The price to earnings (P/E) ratio for Adverum Biotechnologies (ADVM) stock is 0 as of April 13, 2024.

Does Adverum Biotechnologies stock pay dividends?

No, Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Adverum Biotechnologies dividend payment date?

Adverum Biotechnologies (ADVM) stock does not pay dividends to its shareholders.

What is the beta indicator for Adverum Biotechnologies?

Adverum Biotechnologies (ADVM) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Adverum Biotechnologies stock price target?

The target price for Adverum Biotechnologies (ADVM) stock is $40, which is 241.01% above the current price of $11.73. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Adverum Biotechnologies stock

Buy or sell Adverum Biotechnologies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing